Skip to content

A Cohort Study on De-Escalation and Bundled Prevention and Treatment Strategies for Acute Pancreatitis Based on TCM Syndrome Differentiation and Critical Care Ultrasound Monitoring of Physiological Responses

A Cohort Study on De-Escalation and Bundled Prevention and Treatment Strategies for Acute Pancreatitis Based on TCM Syndrome Differentiation and Critical Care Ultrasound Monitoring of Physiological Responses

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103240
Enrollment
Unknown
Registered
2025-05-27
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe acute pancreatitis

Interventions

Acute pancreatitis observation group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old and <= 80 years old; 2. Early pancreatitis participants who meet the diagnostic criteria for AP in the revised 2012 Atlanta guidelines; 3. Onset <= 2 weeks; 4. Participants who are expected to be hospitalized for more than 72 hours.

Exclusion criteria

Exclusion criteria: 1. Refuse to sign the informed consent form; 2. Combine participants with advanced and terminal malignant tumors;

Design outcomes

Primary

MeasureTime frame
Pancreatic Specialty Tests and Scores(Serum Amylase, Serum Lipase, CRP, WBC Count, ALT, AST, Bilirubin, Blood Glucose, Serum Calcium, Serum Creatinine, BUN, Intra-Abdominal Pressure, CTSI, MCTSI, EPIC Score, BISAP Score, Ranson Score, Marshall Score);Inflammatory Evaluation(Temperature (°C), WBC, Absolute Neutrophil Count, Absolute Lymphocyte Count, IL-6, PCT, CRP);Immune Evaluation(Absolute Lymphocyte Count, CD4 (Abs/%), CD8 (Abs/%), CD4/CD8 Ratio, B Cells (Abs/%), NK Cells (Abs/%), Monocytes, Th1/Th2, Blood Cell Count, Reticulocyte Count, Nucleated RBC Count, C3/C4, Immunoglobulins (IgA/IgM/IgG), Tregs, mHLA-DR);Coagulation Evaluation(PLT, PT, APTT, INR, TT, FDP, D-Dimer, PC, PS, vWF, AT?, FIB, TEG, ACT, CR, PF, PIC, t-PAIC, TAT, TM);Endocrine System(Blood/Urine Catecholamines, FT3, FT4, TT3, TT4, ACTH, PTH, Renin, Angiotensin, Aldosterone, Max/Min Blood Glucose, Glucose Variability, HbA1c, Glycated Albumin);Neural Response(5s Sternal Rub,observe the changes before and after:Immediate HR/SBP/DBP/PI Variability Rate [(Post-Stimulus Value - Baseline)/Baseline], 3-Minute HR/BP/PI Recovery Rate [(Post-Stimulus - 3-Min Post-Stimulus)/(Post-Stimulus - Baseline)]);Autonomic Function(Respiratory Rate, HRV, Pupillary Response, Rapid Breathing Test, Breath-Holding Test, Postural Adjustment Test);Biometabolic Indicators(Temperature, Lactate, Free Fatty Acids, ß-Hydroxybutyrate, Albumin, Prealbumin, TG, TC, LDL-C, HDL-C);Organ Function Indicators(BNP, Troponin, CK-MB, Creatinine, GFR, BUN, Serum Cystatin C, TBIL, IBIL, DBIL, ALP, ALT, AST, Albumin, Globulin, PaO2/FiO2);Visualization indicators of Critical Care Ultrasound;Treatment Indicators: Circulatory Support(Vasoactive Drugs (Dopamine, Metaraminol, NE, Epi, Nitroglycerin, Methylene Blue—Duration/Dose); Inotropes (Dobutamine, Cedilanid, Milrinone, Levosimendan—Duration/Dose); Fluid Resuscitation (Volume/Type); IABP/ECMO);Treatment Indicators: Respiratory Support(Mode (Nasal Cannula, HFNC, NIV/IMV), FiO2, Ventilator Paramet

Secondary

MeasureTime frame
Basic and Clinical Information(Age, Gender, Height, Weight, Admission Diagnosis, Underlying Diseases, APACHE II Score, SOFA Score, SIRS Score, GCS Score, SpO2, NBP, ABP, CVP, PI, ICP, Intra-Abdominal Pressure, Intake (IV + Enteral), Urine Output, Ultrafiltration Volume (RRT), Stool Output, GRV, pH, PO2, PCO2, HCO3-, BE, Lactate);

Countries

China

Contacts

Public ContactQing Xia; Wanhong Yin

West China Hospital, Sichuan University

179319164@qq.com+86 135 1810 6758

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026